Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 19;9(10):1773-1781.
doi: 10.7150/jca.24577. eCollection 2018.

Current status and future directions of cancer immunotherapy

Hongming Zhang  1 , Jibei Chen  1
Affiliations
Review

Current status and future directions of cancer immunotherapy

Hongming Zhang et al. J Cancer. .

Abstract

In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Recent years' success of cancer immunotherapy including monoclonal antibodies (mAbs), cancer vaccines, adoptive cancer therapy and the immune checkpoint therapy has revolutionized traditional cancer treatment. However, challenges still exist in this field. Personalized combination therapies via new techniques will be the next promising strategies for the future cancer treatment direction.

Keywords: cancer; cancer immunotherapy; challenges; future directions; immune system.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Important events in the history of cancer immunotherapy. BCG, bacilli Calmette-Guérin; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; FDA, Food and Drug Administration; IFNα, interferon-α; IL-2, interleukin-2; MHC, major histocompatibilty complex; PD-1, programmed death 1; TNF, tumor necrosis factor; VIN, vulvar intraepithelial neoplasia
Figure 2
Figure 2
Depicture of cells in the innate and adaptive immune system
Figure 3
Figure 3
Methods of immunotherapy. MDSC, myeloid-derived suppressor cells; PD-1, programmed death-1; PD-L1, programmed death-ligand 1
See this image and copyright information in PMC

References

    1. Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2012;31:4257–65. - PubMed
    1. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707–23. - PMC - PubMed
    1. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. European journal of pharmacology. 2009;625:41–54. - PMC - PubMed
    1. Barton MK. Daily aspirin may reduce mortality from prostate cancer with risk of high recurrence. CA: a cancer journal for clinicians. 2015;65:83–4. - PubMed
    1. Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr. et al. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. Nature nanotechnology. 2017;5:50. - PMC - PubMed